CTLT Insider Trading
CTLT | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at CTLT provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2024-11-14 22:46 | 2024-11-11 | Ryan Michelle R | Director | SELL | $59.70 | 2,800 | $167,160 | 10,835 | -20.5% |
| 2024-10-21 18:30 | 2024-10-18 | Ferraro Joseph Anthony | Officer - SVP, General Counsel, CCO | SELL | $59.97 | 320 | $19,190 | 23,967 | -1.3% |
| 2024-09-27 19:01 | 2024-09-26 | McErlane David | Officer - Group President, Biologics | SELL | $59.97 | 1,994 | $119,580 | 36,304 | -5.2% |
| 2024-08-05 19:55 | 2024-08-02 | Hopson Ricky | Officer - Pres. BioProduct Delivery, CoS | SELL | $59.56 | 662 | $39,429 | 29,974 | -2.2% |
| 2024-08-05 19:51 | 2024-08-02 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $59.55 | 666 | $39,660 | 39,635 | -1.7% |
| 2024-08-05 19:45 | 2024-08-02 | Ferraro Joseph Anthony | Officer - SVP, General Counsel, CCO | SELL | $59.58 | 608 | $36,225 | 24,287 | -2.4% |
| 2024-08-05 19:39 | 2024-08-02 | Evoli Lisa | Officer - SVP, Chief HR Officer | SELL | $59.67 | 3,859 | $230,267 | 39,366 | -8.9% |
| 2024-08-05 19:33 | 2024-08-02 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $59.55 | 1,169 | $69,614 | 113,724 | -1.0% |
| 2024-07-30 23:53 | 2024-07-29 | Maselli Alessandro | Director, Officer - President & CEO | SELL | $58.76 | 9,088 | $534,011 | 177,521 | -4.9% |
| 2024-07-30 23:45 | 2024-07-29 | Hopson Ricky | Officer - Pres. BioProduct Delivery, CoS | SELL | $58.67 | 206 | $12,086 | 30,636 | -0.7% |
| 2024-07-30 23:39 | 2024-07-29 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $58.69 | 283 | $16,609 | 40,301 | -0.7% |
| 2024-07-30 23:30 | 2024-07-29 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $58.70 | 349 | $20,486 | 114,893 | -0.3% |
| 2024-07-10 23:56 | 2024-07-08 | Masanovich Matti | Officer - SVP, Chief Financial Officer | SELL | $56.74 | 2,993 | $169,823 | 33,871 | -8.1% |
| 2024-06-06 04:35 | 2024-06-04 | Hopson Ricky | Officer - Pres. BioProduct Delivery, CoS | SELL | $54.26 | 1,401 | $76,023 | 20,617 | -6.4% |
| 2024-03-19 20:38 | 2024-03-15 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $56.20 | 387 | $21,749 | 29,506 | -1.3% |
| 2023-09-06 01:00 | 2023-08-31 | Ryan Michelle R | Director | BUY | $49.98 | 1,000 | $49,980 | 1,979 | +102.1% |
| 2023-09-01 20:52 | 2023-08-30 | GREISCH JOHN J | Director, Officer - Executive Chair | BUY | $50.24 | 21,000 | $1,055,040 | 34,000 | +161.5% |
| 2023-08-26 02:16 | 2023-08-24 | Maselli Alessandro | Director, Officer - President & CEO | SELL | $44.54 | 2,071 | $92,245 | 88,004 | -2.3% |
| 2023-08-26 02:12 | 2023-08-24 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $44.57 | 269 | $11,989 | 29,932 | -0.9% |
| 2023-08-26 02:08 | 2023-08-24 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $44.50 | 390 | $17,355 | 24,449 | -1.6% |
| 2023-08-26 02:05 | 2023-08-24 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $44.49 | 396 | $17,618 | 96,552 | -0.4% |
| 2023-08-26 01:58 | 2023-08-24 | Carletti Lorenzo | Officer - SVP Global Ops Ph & Cons Hlth | SELL | $44.71 | 216 | $9,657 | 8,746 | -2.4% |
| 2023-08-26 01:56 | 2023-08-24 | Arnold Jonathan | Officer - SVP, CCO & Div. Head BioP Del. | SELL | $44.87 | 87 | $3,904 | 57,399 | -0.2% |
| 2023-08-26 01:52 | 2023-08-24 | Hopson Ricky | Officer - Pres. Clinical Dev Supply Div | SELL | $44.56 | 276 | $12,299 | 22,040 | -1.2% |
| 2023-08-26 01:48 | 2023-08-24 | Hawkeswood Thomas W | Officer - Pres. Pharma Prod Delivery Div | SELL | $44.72 | 147 | $6,574 | 7,533 | -1.9% |
| 2023-08-26 01:45 | 2023-08-24 | Lickfold Charles | Officer - SVP, CIO | SELL | $44.72 | 190 | $8,497 | 11,339 | -1.6% |
| 2023-08-26 01:39 | 2023-08-24 | Hunt Patricia | Officer - Pres. Consumer Health Div | SELL | $44.77 | 106 | $4,746 | 11,289 | -0.9% |
| 2023-08-26 01:37 | 2023-08-24 | Pravda Ricardo | Officer - Chief Transformation Officer | SELL | $44.47 | 379 | $16,854 | 30,224 | -1.2% |
| 2023-08-26 02:02 | 2023-08-24 | Fasman Steven L | Officer - EVP & Chief Admin Officer | SELL | $44.65 | 817 | $36,479 | 73,789 | -1.1% |
| 2023-08-04 00:13 | 2023-08-01 | Pravda Ricardo | Officer - Chief Transformation Officer | SELL | $47.56 | 269 | $12,793 | 19,739 | -1.3% |
| 2023-08-04 00:05 | 2023-08-01 | Maselli Alessandro | Director, Officer - President & CEO | SELL | $47.13 | 1,485 | $69,995 | 86,101 | -1.7% |
| 2023-08-04 00:00 | 2023-08-01 | Lickfold Charles | Officer - SVP, CIO | SELL | $47.90 | 135 | $6,467 | 5,570 | -2.4% |
| 2023-08-03 23:51 | 2023-08-01 | Hunt Patricia | Officer - Pres. Consumer Health Div | SELL | $47.95 | 161 | $7,720 | 9,154 | -1.7% |
| 2023-08-03 23:47 | 2023-08-01 | Hopson Ricky | Officer - Pres. Clinical Dev Supply Div | SELL | $47.86 | 195 | $9,333 | 16,257 | -1.2% |
| 2023-08-03 23:41 | 2023-08-01 | Hawkeswood Thomas W | Officer - Pres. Pharma Prod Delivery Div | SELL | $47.97 | 258 | $12,376 | 5,106 | -4.8% |
| 2023-08-03 23:37 | 2023-08-01 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $47.90 | 190 | $9,101 | 23,798 | -0.8% |
| 2023-08-03 23:30 | 2023-08-01 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $47.72 | 276 | $13,171 | 17,516 | -1.6% |
| 2023-08-03 23:21 | 2023-08-01 | Gennadios Aristippos | Officer - Group Pres. Pharma & Consumer | SELL | $47.59 | 281 | $13,373 | 86,488 | -0.3% |
| 2023-08-03 23:16 | 2023-08-01 | Carletti Lorenzo | Officer - SVP Global Ops Ph & Cons Hlth | SELL | $47.77 | 383 | $18,296 | 4,602 | -7.7% |
| 2023-08-03 23:09 | 2023-08-01 | Arnold Jonathan | Officer - SVP, CCO & Div. Head BioP Del. | SELL | $47.80 | 62 | $2,964 | 55,896 | -0.1% |
| 2023-08-03 23:02 | 2023-08-01 | Fasman Steven L | Officer - EVP & Chief Admin Officer | SELL | $47.05 | 1,637 | $77,026 | 60,216 | -2.6% |
| 2023-05-04 02:00 | 2023-05-01 | Boerman Manja | Officer - Pres. BioModalities Division | SELL | $49.86 | 1,446 | $72,098 | 14,414 | -9.1% |
| 2023-05-04 01:58 | 2023-05-01 | Gargiulo Mario | Officer - SVP, Ops, Biologics Europe | SELL | $49.86 | 678 | $33,805 | 5,676 | -10.7% |
| 2023-01-26 01:06 | 2023-01-23 | Hopson Ricky | Officer - Pres. Clinical Dev Supply Div | SELL | $49.36 | 643 | $31,738 | 16,452 | -3.8% |
| 2022-12-08 00:51 | 2022-12-05 | Boerman Manja | Officer - Pres. BioModalities Division | SELL | $51.70 | 780 | $40,326 | 15,860 | -4.7% |
| 2022-11-03 02:58 | 2022-10-31 | Grippo Michael J | Officer - SVP, Strategy & Corp. Dev. | SELL | $65.83 | 2,451 | $161,349 | 17,792 | -12.1% |
| 2022-10-13 01:13 | 2022-10-10 | Hawkeswood Thomas W | Officer - Pres. Pharma Prod Delivery Div | SELL | $77.46 | 930 | $72,038 | 5,364 | -14.8% |
| 2022-09-02 21:43 | 2022-08-31 | Hopson Ricky | Officer - Pres. Clinical Dev Supply Div | SELL | $89.59 | 2,216 | $198,531 | 17,095 | -11.5% |
| 2022-08-30 21:38 | 2022-08-26 | Riley Michael A. | Officer - Pres. Bio Product Delivery Div | SELL | $104.07 | 2,491 | $259,238 | 6,592 | -27.4% |
| 2022-08-30 21:37 | 2022-08-26 | Gunther Scott | Officer - SVP, Quality & Reg. Affairs | SELL | $104.07 | 1,639 | $170,571 | 23,988 | -6.4% |
How to Interpret $CTLT Trades
Not every insider transaction in CTLT is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CTLT shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CTLT
Insider activity data for CTLT is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CTLT, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.